127.73
price up icon0.85%   0.815
 
loading
前日終値:
$126.92
開ける:
$127.2
24時間の取引高:
62,829
Relative Volume:
0.04
時価総額:
$19.85B
収益:
$9.82B
当期純損益:
$1.48B
株価収益率:
12.61
EPS:
10.13
ネットキャッシュフロー:
$2.30B
1週間 パフォーマンス:
+0.76%
1か月 パフォーマンス:
-0.30%
6か月 パフォーマンス:
-15.40%
1年 パフォーマンス:
-44.03%
1日の値動き範囲:
Value
$126.74
$128.25
1週間の範囲:
Value
$123.21
$129.27
52週間の値動き範囲:
Value
$110.03
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
名前
Biogen Inc
Name
セクター
Healthcare (1171)
Name
電話
(781) 464-2000
Name
住所
225 BINNEY STREET, CAMBRIDGE, MA
Name
職員
7,605
Name
Twitter
@biogen
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
BIIB's Discussions on Twitter

BIIB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
127.75 19.85B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
802.16 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.41 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.83 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
186.56 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
120.56 234.21B 53.22B 12.86B 14.85B 6.39

Biogen Inc Stock (BIIB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 ダウングレード HSBC Securities Buy → Hold
2025-04-04 ダウングレード Argus Buy → Hold
2025-02-11 開始されました Bernstein Mkt Perform
2025-01-02 ダウングレード Piper Sandler Overweight → Neutral
2024-12-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-12-16 ダウングレード Stifel Buy → Hold
2024-12-10 再開されました BofA Securities Neutral
2024-12-09 ダウングレード Jefferies Buy → Hold
2024-11-18 ダウングレード Needham Buy → Hold
2024-11-15 開始されました Wolfe Research Peer Perform
2024-11-14 開始されました Citigroup Neutral
2024-10-31 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-10-10 再開されました Raymond James Mkt Perform
2024-02-14 繰り返されました Needham Buy
2024-02-14 ダウングレード Wells Fargo Overweight → Equal Weight
2024-01-24 ダウングレード UBS Buy → Neutral
2023-12-20 再開されました Cantor Fitzgerald Overweight
2023-12-07 アップグレード Raymond James Mkt Perform → Outperform
2023-09-06 開始されました HSBC Securities Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-24 繰り返されました UBS Buy
2023-05-01 アップグレード Guggenheim Neutral → Buy
2023-04-17 アップグレード Piper Sandler Neutral → Overweight
2022-10-26 アップグレード Goldman Neutral → Buy
2022-10-13 アップグレード Stifel Hold → Buy
2022-10-07 アップグレード Argus Hold → Buy
2022-09-28 アップグレード BMO Capital Markets Market Perform → Outperform
2022-09-28 アップグレード Mizuho Neutral → Buy
2022-09-28 アップグレード Robert W. Baird Neutral → Outperform
2022-04-18 アップグレード Wells Fargo Equal Weight → Overweight
2022-03-08 ダウングレード Stifel Buy → Hold
2022-03-03 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-04 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-04 繰り返されました Barclays Equal Weight
2022-02-04 繰り返されました BofA Securities Neutral
2022-02-04 繰り返されました Cowen Outperform
2022-02-04 繰り返されました Morgan Stanley Overweight
2022-02-04 繰り返されました Needham Buy
2022-02-04 繰り返されました Oppenheimer Outperform
2022-02-04 繰り返されました RBC Capital Mkts Sector Perform
2022-02-04 繰り返されました Robert W. Baird Neutral
2022-02-04 繰り返されました Wedbush Neutral
2022-02-04 繰り返されました Wells Fargo Equal Weight
2022-02-04 繰り返されました Wolfe Research Peer Perform
2022-01-13 ダウングレード Guggenheim Buy → Neutral
2022-01-12 ダウングレード Piper Sandler Overweight → Neutral
2021-12-10 再開されました Raymond James Mkt Perform
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 開始されました BMO Capital Markets Outperform
2021-09-23 開始されました Needham Buy
2021-06-18 アップグレード Piper Sandler Neutral → Overweight
2021-06-14 繰り返されました Truist Buy
2021-06-11 アップグレード Bernstein Mkt Perform → Outperform
2021-06-10 アップグレード UBS Neutral → Buy
2021-06-08 アップグレード Atlantic Equities Underweight → Neutral
2021-06-08 繰り返されました Barclays Equal Weight
2021-06-08 アップグレード Citigroup Sell → Neutral
2021-06-08 繰り返されました H.C. Wainwright Buy
2021-06-08 繰り返されました Jefferies Buy
2021-06-08 繰り返されました Morgan Stanley Overweight
2021-06-08 繰り返されました RBC Capital Mkts Sector Perform
2021-06-08 アップグレード Robert W. Baird Underperform → Neutral
2021-06-08 繰り返されました Stifel Buy
2021-06-08 アップグレード William Blair Mkt Perform → Outperform
2021-06-07 アップグレード BofA Securities Underperform → Neutral
2021-06-07 アップグレード Cowen Market Perform → Outperform
2021-06-07 アップグレード Raymond James Underperform → Mkt Perform
2021-02-05 ダウングレード DZ Bank Buy → Hold
2021-01-29 アップグレード Stifel Hold → Buy
2020-11-10 アップグレード DZ Bank Hold → Buy
2020-11-09 ダウングレード Atlantic Equities Neutral → Underweight
2020-11-09 ダウングレード BofA Securities Neutral → Underperform
2020-11-09 ダウングレード Cowen Outperform → Market Perform
2020-11-09 繰り返されました H.C. Wainwright Buy
2020-11-04 アップグレード BofA Securities Underperform → Neutral
2020-11-04 アップグレード Jefferies Hold → Buy
2020-11-04 アップグレード Wells Fargo Equal Weight → Overweight
2020-10-28 開始されました UBS Neutral
2020-07-27 アップグレード Morgan Stanley Underweight → Overweight
2020-06-22 ダウングレード Barclays Overweight → Equal Weight
2020-06-22 繰り返されました RBC Capital Mkts Sector Perform
2020-06-09 ダウングレード Bernstein Outperform → Mkt Perform
2020-04-23 ダウングレード Citigroup Neutral → Sell
2020-04-23 ダウングレード Raymond James Mkt Perform → Underperform
2020-03-31 開始されました Wolfe Research Peer Perform
2020-02-27 開始されました Barclays Overweight
2020-01-27 アップグレード Canaccord Genuity Hold → Buy
2019-12-13 アップグレード Credit Suisse Underperform → Neutral
2019-12-02 ダウングレード Robert W. Baird Neutral → Underperform
すべてを表示

Biogen Inc (BIIB) 最新ニュース

pulisher
Jun 18, 2025

Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Dips on Its Part in BRAVE Study - Baystreet.ca

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen

Jun 18, 2025
pulisher
Jun 18, 2025

How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen patents new HTT splicing modulators - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media

Jun 17, 2025
pulisher
Jun 16, 2025

NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 15, 2025

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Biogen Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen: positive Phase 3 data in lupus - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus

Jun 12, 2025

Biogen Inc (BIIB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$48.28
price down icon 0.13%
$107.07
price up icon 2.01%
drug_manufacturers_general PFE
$24.32
price up icon 0.35%
$278.56
price down icon 0.88%
drug_manufacturers_general MRK
$79.05
price down icon 0.70%
drug_manufacturers_general NVS
$120.06
price down icon 0.13%
大文字化:     |  ボリューム (24 時間):